BeStock  
Stocks › Biotechnology › HALO

Halozyme Therapeutics HALO

US equityMarket cap rank #1380Biotechnology
$91.35 −$1.69 (-1.82%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $91.35 0.00%
Open$93.64
Prev close$93.04
Day range$90.79 – $93.64
Volume1.50M
Market cap$10.41B
P/E (TTM)22.8
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$492.97M+39.2% YoY
Operating profit$294.97M+35.4% YoY
Net profit$247.05M+41.0% YoY
Diluted EPS$2.01+40.6% YoY
Free cash flow$255.22M+45.4% YoY
Operating cash flow$258.27M

Revenue, last 8 quarters

$298.0MDec '24$264.9MMar '25$325.7MJun '25$354.3MSep '25$451.8MDec '25$376.7MMar '26$481.0MJun '26$493.0MSep '26

Net profit, last 8 quarters

$137.0MDec '24$118.1MMar '25$165.2MJun '25$175.2MSep '25$-141.6MDec '25$150.0MMar '26$229.9MJun '26$247.0MSep '26

Diluted EPS by quarter

1.06Dec '240.93Mar '251.33Jun '251.43Sep '25-1.20Dec '251.22Mar '261.90Jun '262.01Sep '26

Free cash flow by quarter

$175.4MDec '24$153.3MMar '25$98.1MJun '25$175.6MSep '25$-70.2MDec '25$176.3MMar '26$236.7MJun '26$255.2MSep '26

Annual revenue

$267.6MFY20$443.3MFY21$660.1MFY22$829.3MFY23$1.0BFY24$1.4BFY25

Profitability & balance sheet

Gross margin82.3%
Operating margin55.9%
Net margin26.9%
Return on equity216.4%
Return on assets17.0%
Return on invested capital19.3%
Current ratio3.88
Liabilities / assets101.6%
Cash & investments$1.07B
Total debt$3.25B
Net cash (debt)-$2.18B
Free cash flow / sales33.2%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $492.97M $481.00M $376.71M $1.40B $451.77M
Total Operating Revenue $492.97M $481.00M $376.71M $1.40B $451.77M
Cost of Revenue $82.48M $79.17M $79.24M $228.77M $78.77M
Gross Profit $410.50M $401.83M $297.47M $1.17B $373.00M
Operating Expense $115.53M $114.17M $112.95M $365.24M $132.30M
Selling and Admin Expenses $58.24M $57.00M $57.88M $207.09M $77.03M
Research & Development $27.78M $27.66M $25.56M $81.49M $31.90M
Depreciation & Amortization & Depletion $29.51M $29.51M $29.51M $76.66M $23.38M
-Depreciation & Amortization $29.51M $29.51M $29.51M $76.66M $23.38M
Operating Profit $294.97M $287.65M $184.52M $802.59M $240.70M
Net Non-Operating Interest Income (Expense) -$6.05M -$5.59M -$5.51M -$18.13M -$4.91M
Non-Operating Interest Expense $6.05M $5.59M $5.51M $18.13M $4.91M
Other Income (Expense) $1.71M $2.84M $1.32M -$317.59M -$336.63M
Gain on Sale of Security $2.17M $2.84M $1.32M $21.47M $2.43M
Special Income (Charges) -$465,000.00 – – -$339.06M -$339.06M
-Less:Other Special Charges $465,000.00 – – $5.48M –
Pretax Profit $290.63M $284.90M $180.33M $466.88M -$100.85M
Tax $43.58M $54.99M $30.28M $149.99M $40.74M
Net Profit $247.05M $229.91M $150.05M $316.89M -$141.59M
Profit from Continuing Operations $247.05M $229.91M $150.05M $316.89M -$141.59M
Net Income to Parent Company $247.05M $229.91M $150.05M $316.89M -$141.59M
Net Income to Common Stockholders $247.05M $229.91M $150.05M $316.89M -$141.59M
Basic EPS $2.17 $1.96 $1.27 $2.64 -$1.20
Diluted EPS $2.01 $1.90 $1.22 $2.56 -$1.20
-Less:Restructuring and Mergern & Acquisition – – – $284.89M –
-Less:Impairment of Capital Assets – – – $48.70M –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $3.47B $2.58B $2.67B $2.53B $2.53B
Total Current Assets $1.85B $933.02M $1.00B $825.21M $825.21M
Cash and Cash Equivalents & Short-Term Investments $1.07B $231.00M $318.62M $142.82M $142.82M
-Cash and Cash Equivalents $1.03B $163.14M $309.75M $133.82M $133.82M
-Short Term Investments $44.40M $67.87M $8.87M $9.00M $9.00M
Receivables $525.59M $455.83M $457.99M $441.27M $441.27M
-Accounts Receivable $529.51M $461.99M $468.25M $434.27M $434.27M
-Other Receivables $7.00M $2.50M – $16.61M $16.61M
-Receivables Adjustments Allowances -$10.92M -$8.66M -$10.26M -$9.61M -$9.61M
Inventory $132.61M $137.14M $155.47M $176.48M $176.48M
Other Current Assets $114.14M $109.06M $70.96M $64.64M $64.64M
Total Non-Current Assets $1.63B $1.64B $1.67B $1.70B $1.70B
Net PPE $82.29M $84.27M $82.23M $82.14M $82.14M
-Gross PPE $118.24M $118.21M $117.45M $115.30M $115.30M
-Accumulated Depreciation -$35.95M -$33.94M -$35.22M -$33.16M -$33.16M
Goodwill and Other Intangible Assets $1.47B $1.50B $1.53B $1.56B $1.56B
-Goodwill $581.73M $581.73M $582.32M $580.36M $580.36M
-Other Intangible Assets $892.93M $922.44M $951.96M $981.47M $981.47M
Other Non-Current Assets $69.67M $55.94M $53.18M $56.15M $56.15M
Total Liabilities $3.53B $2.43B $2.45B $2.48B $2.48B
Total Current Liabilities $476.09M $344.44M $363.21M $177.09M $177.09M
Payables $33.55M $23.61M $14.10M $20.90M $20.90M
-Accounts Payable $33.55M $23.61M $14.10M $20.90M $20.90M
Current Accrued Expenses $136.93M $111.86M $140.37M $156.19M $156.19M
Short-Term Debt and Capital Lease Obligation $305.61M $208.97M $208.74M – –
-Current Debt $305.61M $208.97M $208.74M – –
Total Non-Current Liabilities $3.05B $2.09B $2.09B $2.30B $2.30B
Long Term Debt and Capital Lease Obligation $2.94B $1.94B $1.94B $2.14B $2.14B
-Long Term Debt $2.94B $1.94B $1.94B $2.14B $2.14B
Non-Current Deferred Liabilities $6.34M $49.06M $47.53M $42.92M $42.92M
Other Non-Current Liabilities $101.47M $102.68M $106.45M $113.86M $113.86M
Total Equity -$55.24M $143.54M $219.64M $48.81M $48.81M
Stockholders' Equity -$55.24M $143.54M $219.64M $48.81M $48.81M
Capital Stock $114,000.00 $114,000.00 $118,000.00 $118,000.00 $118,000.00
-Common Stock $114,000.00 $114,000.00 $118,000.00 $118,000.00 $118,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $0.00 $0.00 $27.39M $12.00M $12.00M
Retained Earnings -$58.13M $151.26M $204.84M $54.79M $54.79M
Gains/Losses Not Affecting Retained Earnings $2.78M -$7.83M -$12.70M -$18.09M -$18.09M
Non-Current Deferred Assets – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $258.27M $240.89M $180.08M $651.56M $219.03M
Net cash flow from continuing operations $258.27M $240.89M $180.08M $651.56M $219.03M
Net Income from Continuing Operations $247.05M $229.91M $150.05M $316.89M -$141.59M
Gain/Loss from Continuing Operations $0.00 – – $2.45M $2.38M
Depreciation & Depletion & Amortization $34.20M $33.97M $33.73M $88.05M $26.68M
Deferred Tax -$5.15M $907,000.00 $3.43M $634,000.00 -$16.77M
Other Non-Cash Items $2.95M $2.47M $2.46M $298.82M $292.59M
Change in Working Capital -$37.03M -$43.57M -$26.20M -$152.26M -$9.43M
-Change in Receivables -$69.77M $2.16M -$19.55M -$128.06M -$90.48M
-Change in Inventory $5.04M $18.33M $27.38M $2.55M $18.78M
-Change in Prepaid Assets -$13.21M -$41.15M -$9.11M -$32.96M $28.42M
-Change in Payables and Accrued Expense $40.90M -$22.91M -$24.92M $6.21M $33.85M
Net cash flow from investing $20.95M -$62.66M -$2.88M -$545.81M -$741.79M
Net Cash Flow from Continuing Investing Activities $20.95M -$62.66M -$2.88M -$545.81M -$741.79M
Net PPE Purchase and Sale -$3.05M -$4.17M -$3.74M -$6.97M -$1.43M
Net Business Purchase and Sale $0.00 $0.00 $710,000.00 -$725.97M -$725.97M
Net Investment Purchase and Sale $24.00M -$58.49M $154,000.00 $474.89M $273.38M
Financing Cash Flow $587.65M -$326.25M -$1.61M -$85.17M $239.52M
Net Cash Flow from Continuing Financing Activities $587.65M -$326.25M -$1.61M -$85.17M $239.52M
Net Common Stock Issuance -$67.27M – – -$342.37M $0.00
Proceeds from Stock Option Exercised $22.80M $6.48M -$1.61M $21.83M $4.15M
Ending Cash Balance $1.03B $163.99M $312.01M $136.42M $136.42M
Net Change in Cash $866.86M -$148.02M $175.59M $20.57M -$283.24M
Beginning Cash Balance $163.99M $312.01M $136.42M $115.85M $419.67M
Free Cash Flow $255.22M $236.72M $176.34M $356.82M -$70.17M
Net Intangibles Purchase and Sale – – – -$287.77M –
Net Issuance Payments Of Debt – – – $451.13M $451.13M
Net Other Financing Charges – – – -$215.76M –

Discussion

No comments yet — be the first to weigh in on HALO.

Sign in to join the discussion.

Scroll to Top